Top-News
Biotechnologie USA

Xencor Inc News

Aktie
WKN:  A1W96L ISIN:  US98401F1057 US-Symbol:  XNCR
20,70 €
+0,20 €
+0,98%
07:52:31 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
60,88 Mio.
Marktkapitalisierung *
1,26 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 13.02.2024

Xencor Inc News

09.05.24 - Businesswire
Xencor Reports First Quarter 2024 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-​stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported ...
09.04.24 - Businesswire
Xencor Appoints Bart Cornelissen as Chief Financial Officer
Xencor, Inc. (NASDAQ:XNCR), a clinical-​stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today ...
28.02.24 - Businesswire
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-​stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today ...
27.02.24 - Businesswire
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-​stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported ...
20.02.24 - Businesswire
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
Xencor, Inc. (NASDAQ: XNCR), a clinical-​stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, ...
05.01.23 - PR Newswire
Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates
Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates PR Newswire
02.08.22 - PR Newswire
Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies
Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies PR Newswire
25.02.19 - PR Newswire
Xencor Reports Fourth Quarter and Full Year 2018 Financial Results
Xencor Reports Fourth Quarter and Full Year 2018 Financial Results - Initial Data from Phase 1 Study of XmAb®14045 Presented at ASH 2018; Multiple Complete Remissions ...
20.02.19 - PR Newswire
Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045
Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045 PR Newswire
19.02.19 - PR Newswire
Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019
Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019 PR Newswire
07.02.19 - PR Newswire
Xencor to Present at Upcoming Investor Conferences
Xencor to Present at Upcoming Investor Conferences PR Newswire
05.02.19 - PR Newswire
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech -- Xencor Receives $120 Million Upfront Payment, up to $180 Million in Development ...
07.01.19 - PR Newswire
Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody
Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody -- Initial data from the ongoing Phase 1 study in patients with B-cell malignancies ...
03.12.18 - PR Newswire
Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting PR Newswire
08.11.18 - PR Newswire
Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors
Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors PR Newswire
05.11.18 - PR Newswire
Xencor Reports Third Quarter 2018 Financial Results
Xencor Reports Third Quarter 2018 Financial Results - Initial Data from Phase 1 Dose-​Escalation Study of XmAb®14045 in Acute Myeloid Leukemia (AML) to Be Presented at 2018 ...
01.11.18 - PR Newswire
Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting PR Newswire
29.10.18 - PR Newswire
Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018
Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018 PR Newswire
05.10.18 - PR Newswire
Xencor Announces Topline Results from Phase 2 Study of XmAb®5871 in Systemic Lupus Erythematosus and Selection of Late-Breaking Abstract for Presentation at the 2018 ACR Annual Meeting
Xencor Announces Topline Results from Phase 2 Study of XmAb®5871 in Systemic Lupus Erythematosus and Selection of Late-​Breaking Abstract for Presentation at the 2018 ACR ...
25.09.18 - PR Newswire
Xencor to Participate in Upcoming Investor Conferences
Xencor to Participate in Upcoming Investor Conferences PR Newswire

Newssuche

Videos

14.05.24 -16,04%
Technical Trading: DAX dienstags Long
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »